aducanumab | Aducanumab

Keyword	CPC	PCC	Volume	Score	Length of keyword
aducanumab	1.83	0.9	7253	35	10

Keyword	CPC	PCC	Volume	Score
aducanumab	0.21	1	6563	84
aducanumab website	0.36	1	8786	5
aducanumab fda approval	0.34	0.8	6594	8
aducanumab cost	0.71	0.5	9365	47
aducanumab vs lecanemab	1.19	0.5	5241	57
aducanumab alzheimer	0.62	0.7	6310	62
aducanumab fda	0.75	0.7	5543	98
aducanumab controversy	0.18	0.8	3754	55
aducanumab side effects	1.65	0.4	1236	94
aducanumab biogen	1.16	0.7	8929	88
aducanumab pronunciation	1.55	0.5	60	81
aducanumab dementia	0.73	0.3	7486	17
aducanumab-avwa	0.43	0.5	8173	40
aducanumab mechanism of action	1.63	0.5	4345	88
aducanumab aduhelm	1.74	0.8	8928	64
aducanumab brand name	1.3	0.2	7481	79
aducanumab approval	1.74	0.4	410	55
aducanumab phase 3	0.25	0.9	1965	50
aducanumab package insert	0.46	0.6	5948	79

Search Results related to aducanumab on Search Engine

Aducanumab - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Aducanumab

WEBAducanumab, sold under the brand name Aduhelm, is a medication designed to treat Alzheimer's disease (AD). It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. It was developed by Biogen and Eisai.

DA: 65 PA: 37 MOZ Rank: 13

Aducanumab to Be Discontinued as Alzheimer’s Treatment | alz.org
alz.org

https://www.alz.org/alzheimers-dementia/treatments/aducanumab

WEBAducanumab (Aduhelm), a treatment for Alzheimer’s disease, will be discontinued by its manufacturer (Biogen) in 2024. Get information and resources for Alzheimer's and other dementias from the Alzheimer's Association.

DA: 81 PA: 18 MOZ Rank: 57

Aducanumab - StatPearls - NCBI Bookshelf
nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK573062/

WEBJun 3, 2023 · Aducanumab is a medication used in the management and treatment of Alzheimer disease. It is an amyloid beta-directed monoclonal antibody. This activity describes the indications, action, and contraindications for aducanumab as a possible agent in the management of Alzheimer disease.

DA: 71 PA: 68 MOZ Rank: 76

Aducanumab Uses, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/mtm/aducanumab.html

WEBMar 10, 2023 · Generic name: aducanumab [ A-due-KAN-ue-mab ] Brand name: Aduhelm. Dosage form: intravenous solution (avwa 100 mg/mL) Drug class: Miscellaneous central nervous system agents. Medically reviewed by Drugs.com on Mar 10, 2023. Written by Cerner Multum. Uses. Side effects. Warnings. Before taking. Dosage. Interactions. What …

DA: 62 PA: 80 MOZ Rank: 54

What to Know About the Alzheimer Drug Aducanumab (Aduhelm)
jamanetwork.com

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2792897

WEBWhat Is Aducanumab? The FDA recently approved aducanumab (Aduhelm) for people with mild symptoms of Alzheimer disease, such as individuals who are still independent in basic daily functioning. It reduced brain amyloid plaque (protein deposits), a main feature of Alzheimer disease.

DA: 6 PA: 30 MOZ Rank: 39

Aducanumab: evidence from clinical trial data and controversies
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491638/

WEBOn 7 June 2021, the US FDA approved aducanumab, a human IgG1 anti-Aβ monoclonal antibody selective for Aβ aggregates, as the first disease-modifying treatment for AD. Aducanumab is approved in the United States for the treatment of mild cognitive impairment or mild-dementia stage of AD.

DA: 33 PA: 2 MOZ Rank: 87

Aduhelm | ALZFORUM
alzforum.org

https://www.alzforum.org/therapeutics/aduhelm

WEBJan 3, 2016 · Synonyms: Aducanumab, BIIB037. Therapy Type: Immunotherapy (passive) (timeline) Target Type: Amyloid-Related (timeline) Condition (s): Alzheimer's Disease. U.S. FDA Status: Company: Biogen, Neurimmune. Background. BIIB037 is a high-affinity, fully human IgG1 monoclonal antibody against a conformational epitope found on Aβ.

DA: 7 PA: 53 MOZ Rank: 60

FDA’s Decision to Approve New Treatment for Alzheimer’s Disease
fda.gov

https://www.fda.gov/drugs/our-perspective/fdas-decision-approve-new-treatment-alzheimers-disease

WEBToday FDA approved Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway, under which the FDA approves a drug for a serious or life-threatening...

DA: 5 PA: 3 MOZ Rank: 61

FDA Grants Accelerated Approval for Alzheimer’s Drug | FDA
fda.gov

https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug

WEBJune 07, 2021. Today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans.

DA: 34 PA: 59 MOZ Rank: 2

Aducanumab: First Approval - PubMed
nih.gov

https://pubmed.ncbi.nlm.nih.gov/34324167/

WEBAducanumab (aducanumab-avwa; Aduhelm™) is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid β. It has been co-developed by Biogen and Eisai under license from Neurimmune for the treatment of Alzheimer's disease. In June 2021 …

DA: 94 PA: 70 MOZ Rank: 86